<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945785</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0443</org_study_id>
    <nct_id>NCT04945785</nct_id>
  </id_info>
  <brief_title>&quot; SAVE Study (Switch AdVagraf® to Envarsus®) for Fast Metabolizers Kidney Transplant Recipients&quot;</brief_title>
  <acronym>SAVE</acronym>
  <official_title>&quot; SAVE Study (Switch AdVagraf® to Envarsus®) for Fast Metabolizers Kidney Transplant Recipients&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of calcineurin inhibitors (CNIs) in kidney transplantation is the gold standard&#xD;
      treatment to prevent episodes of rejection. Nevertheless, CNIs have side effects and are in&#xD;
      particular nephrotoxic for the kidney transplant. Monitoring CNI dosages is fundamental for&#xD;
      the clinician, in order to find the right balance between toxicity and prevention of&#xD;
      rejection. Several recent studies suggest that a Radio Residual Concentration / Dosage (C0 /&#xD;
      D) less than 1.05 (patients with rapid metabolizers) is associated with poor graft function&#xD;
      (eGFR) and decreased kidney transplant survival. LCPT prolonged-release tacrolimus (Novel&#xD;
      Once-Daily Extended-Release Tacrolimus. Prolonged-release tacrolimus: Envarsus®) is a&#xD;
      marketed form of tacrolimus with interesting pharmacokinetic properties: daily intake,&#xD;
      reduction of the absorption peak (Meltodose® technology ) and reduction of the total CNI dose&#xD;
      by 30% to obtain an equivalent CO compared to other molecules on the market (Advagraf®,&#xD;
      Prograf®). Thus, the use of LCPT in patients rapid metabolisers in relay of Advagraf® or&#xD;
      Prograf® could make it possible to decrease renal toxicity while preserving rejection, by&#xD;
      increasing the C0 / D ratio.&#xD;
&#xD;
      The investigators propose a pilot study aiming to study a prospective cohort of rapid&#xD;
      metabolisers patients put on Envarsus at one month of transplant compared to a historical&#xD;
      cohort, in terms of C0 / D ratio, function and survival of the renal graft.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">January 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of kidney allograft between month 1 and month 12</measure>
    <time_frame>12 months</time_frame>
    <description>comparison of eGFR (estimated Glomerular Filtration Rate) level at M12 by using the MDRD formula between Envarsus® and Advagraf® groups.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Renal Transplant Failure</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>Before switch Advagraf to Envarsus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>case</arm_group_label>
    <description>After switch Advagraf to Envarsus</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>case</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Major patients with row 1 or 2 renal transplants (1st or 2nd transplant) rapid metabolizers&#xD;
        defined by a C0 / D ratio &lt;1.05 at one month post transplant, with impaired function of the&#xD;
        graft. 75 patients will be prospectively included in the Advagraf® or Prograf® switch&#xD;
        cohort for Envarsus® during their renal transplant follow-up. 150 patients matched on age,&#xD;
        graft rank, type of donor (standard criteria / expanded criteria) and C0 / D at one month&#xD;
        of grafting will constitute the retrospective control cohort extracted from the database in&#xD;
        Nantes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ≥ 18 years old&#xD;
&#xD;
          -  1st or 2nd kidney transplant&#xD;
&#xD;
          -  Transplantation from a deceased donor (Encephalic death or arrested heart Maastricht&#xD;
             III)&#xD;
&#xD;
          -  C0 / D ratio &lt;1.05 at one month of kidney transplant&#xD;
&#xD;
          -  Renal graft function &lt;60ml / min (eGFR estimate by CKD-EPI or MDRD).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient ≤ 18 years old, under guardianship or protected&#xD;
&#xD;
          -  Graft rank ≥ 3&#xD;
&#xD;
          -  Renal graft function &lt;30 ml / min (eGFR estimate by CKD-EPI or MDRD)&#xD;
&#xD;
          -  Presence of pre-transplant DSA (threshold&gt; 2000 MFI)&#xD;
&#xD;
          -  Occurrence of histologically proven rejection during the 1st month of transplant&#xD;
&#xD;
          -  Presence of another functional transplant (heart / lung / liver / pancreas) or kidney&#xD;
             bi-transplant&#xD;
&#xD;
          -  Transplantation from a living donor&#xD;
&#xD;
          -  Transplantation from an arrested heart donor Maastricht II&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacques DANTAL</last_name>
    <phone>0240087441</phone>
    <email>jacques.dantal@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

